ReviewJournal of neurochemistry2016
Bioenergetics and metabolism: a bench to bedside perspective.
Review in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- lncRNA-associated ceRNA network revealing the potential regulatory roles of ferroptosis and immune infiltration in Alzheimer's disease.Frontiers in aging neuroscience · 2023Article
- Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets.Biomolecules · 2022Review
- Measurement of Mitochondrial Respiration in Platelets.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Assessment of the Effects of Drugs on Mitochondrial Respiration.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Nuclear Factor Erythroid-2-Related Factor 2 Signaling in the Neuropathophysiology of Inherited Metabolic Disorders.Frontiers in cellular neuroscience · 2021Review
- Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Energy Metabolism Decline in the Aging Brain-Pathogenesis of Neurodegenerative Disorders.Metabolites · 2020Review
- Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools.Current neuropharmacology · 2020Review
- Metabolomic Assays of Postmortem Brain Extracts: Pitfalls in Extrapolation of Concentrations of Glucose and Amino Acids to Metabolic Dysregulation In Vivo in Neurological Diseases.Neurochemical research · 2019Article
- Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.British journal of pharmacology · 2019Review
- Dynamin-like protein 1 cleavage by calpain in Alzheimer's disease.Aging cell · 2019Article
- Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.Experimental gerontology · 2018Article
- Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States.Cell metabolism · 2018Review
- Dynamic Changes of the Mitochondria in Psychiatric Illnesses: New Mechanistic Insights From Human Neuronal Models.Biological psychiatry · 2018Review
- Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex.Molecular neurodegeneration · 2018Article
- Mitochondria and Mitochondrial Cascades in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Review
- The Role of Mitochondrial Dysfunction in the Progression of Alzheimer's Disease.Current medicinal chemistry · 2018Review
- Relationship Between β-Amyloid and Mitochondrial Dynamics.Cellular and molecular neurobiology · 2017Review
- Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease.Behavioural brain research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
'Metabolism' refers to the vast collection of chemical processes that occur within a living organism. Within this broad designation, one can identify metabolism events that relate specifically to energy homeostasis, whether they occur at the subcellular, cellular, organ, or whole organism level. This review operationally refers to this type of metabolism as 'energy metabolism' or 'bioenergetics.' Changes in energy metabolism/bioenergetics have been linked to brain aging and a number of neurodegenerative diseases, and research suggests mitochondria may uniquely contribute to this. Interventions that manipulate energy metabolism/bioenergetic function and mitochondria may have therapeutic potential and efforts intended to accomplish this are playing out at basic, translational, and clinical levels. This review follows evolving views of energy metabolism's role in neurodegenerative diseases but especially Alzheimer's disease, with an emphasis on the bench-to-bedside process whose ultimate goal is to develop therapeutic interventions. It further considers challenges encountered during this process, which include linking basic concepts to a medical question at the initial research stage, adapting conceptual knowledge gained to a disease-associated application in the translational stage, extending what has been learned to the clinical arena, and maintaining support for the research at each of these fundamentally linked but functionally distinct stages. A bench-to-bedside biomedical research process is discussed that moves through conceptual, basic, translational, and clinical levels. For example, herein a case was made that bioenergetics is a valid Alzheimer's disease therapeutic target. Following this, a fundamental strategy for manipulating bioenergetics was defined, potential implications studied, and the approach extended to the clinical arena. This article is part of the 60th Anniversary special issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.